Aimeishi Market Research Consulting (Shanghai) Co., Ltd. is responsible for IMS Health's business in China, mainly covering market information survey, releasing survey data to health care industry partners and business consultation.
On July 23, 2004, Shanghai Zhilian Market Research Co., Ltd. (URSH) officially announced its participation in IMS Health, the world's largest medical and health market consulting company.
Shanghai zhilian market research co., ltd. (URC SH) is a professional consulting company specializing in medical and health research under zhilian market research (URC). Founded in 1998, it has been committed to providing professional consulting services such as medical retail market research and medical case consultation for customers in the health care industry. China is a pioneer in pharmaceutical retail market research and a market leader in China at present. At present, it mainly conducts business activities in Shanghai, Beijing, Guangzhou and other 14 cities and regions. Since its establishment six years ago, international big companies including Xi 'an Janssen, Squibb, Sino-American SmithKline, Johnson & Johnson, Roche and well-known domestic big companies such as Sanjiu Pharmaceutical, Yangshengtang and Zheng Qi Tibetan Medicine have become the company's main customers. In terms of the depth and breadth of the retail drug market research in China, URC SH has rich industry experience, accumulated a large number of continuous market data, and a professional team of more than 65,438+0.20 people, which makes URC SH the most competitive advantage in the retail drug market research in China. At present, the data of pharmaceutical retail market provided by URSH is not only an important indicator for some international medical and health care enterprises, but also an important indicator for some leading large pharmaceutical enterprises in China to evaluate their marketing performance, and has become the "evaluation benchmark" for the pharmaceutical retail market in China.